Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer

Lung Cancer

Volumn 22, Issue 1, 1998, Pages 31-38

  Martoni, A ^a   Guaraldi, M ^a   Piana, E ^a   Strocchi, E ^a   Petralia, A ^a   Busutti, L ^a   Preti, P ^b   Robustelli della Cuna, G ^b   Raimondi, M ^c   Ferrara, G ^c   Palomba, G ^d   Lelli, G ^d   Picece, V ^e   Recaldin, E ^e   Caffo, O ^f   Ambrosini, G ^f   Sarobba, G ^g   Farris, A ^g   Pannuti, F ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b IRCCS   (Italy)

^c VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e Ospedale S Cuore   (Italy)

^f SANTA CHIARA HOSPITAL   (Italy)

^g NONE

Author keywords

High dose epirubicin in NSCLC; Non small cell lung cancer; Vinorelbine in NSCLC

Indexed keywords

CISPLATIN; EPIRUBICIN; NAVELBINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG TOXICITY; FEMALE; HEART VENTRICLE ARRHYTHMIA; HISTOLOGY; HUMAN; HYPERPYREXIA; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; ITALY; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0032191525     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(98)00065-8     Document Type: Article

References (23)

1. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J. 311:1995;899-909.
2. Depierre A., Lemarie E., Dabouis G et al. A phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol. 14:1991;115-119.
3. Le Chevalier T., Brisgand D., Douillard J.Y. et al. Randomized study of Vinorelbine and Cisplatin versus Vindesine and Cisplatin versus Vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 12:1994;360-367.
4. Kalman L.A., Kris M.G., Gralla R.J., Kelsen D.P. Phase II trial of 4′Epi-doxorubicin in patients with non-small cell lung cancer. Cancer Treat Rep. 67:1983;591-592.
5. Joss R.A., Hansen H.H., Hansen M., Renards J., Rozencweig M. Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung. Eur J Cancer Clin Oncol. 20:1984;495-499.
6. Martoni A., Giovannini M., Tomasi L A phase II clinical trial of 4′-epidoxorubicin in advanced solid tumors. Cancer Chemother Pharmacol. 12:1984;179-182.
7. Meyers F.J., Cardiff R.D., Quadro R. et al. Epirubicin in non-oat cell lung cancer-response rates and the importance of immunopathology: a northern California oncology group study. Cancer Treat Rep. 70:1986;805-806.
8. Lelli G., Farris A., Casadio M. et al. 4′Epidoxorubicin and cis-diamminedichloroplatinum in advanced non-small cell bronchogenic carcinoma: a phase II study. J Exp Clin Cancer Res. 5:1986;185-190.
9. Holdener EE., Jungi WJ., Fiebig H. Phase I of high dose epirubicin in NSCLC. Proc ASCO. 7:1988;806.
10. Henss H., Fiebig H.H., Holdener E.E., Kaplan E. Phase II study of high-dose epirubicin in non-small cell lung cancer. Contrib Oncol. 37:1989;136-140.
11. Wils J., Utama I., Sala L. et al. Phase II study of high-dose Epirubicin in non-small cell lung cancer. Eur J Cancer. 26:1990;1140-1141.
12. Martoni A., Melotti B., Guaraldi M., Pannuti F. Activity of high-dose Epirubicin in advanced non small cell lung cancer (NSCLC). Eur J Cancer. 27:1991;1231-1234.
13. Feld R., Wierzbicki R., Walde P.L.D. et al. Phase I-II study of high-dose epirubicin in advanced non-small lung cancer. J Clin Oncol. 10:1992;297-303.
14. Martoni A., Guaraldi M., Casadio M., Busutti L., Pannuti F A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 3:1992;864-866.
15. Camaggi C.M., Comparsi R., Strocchi E., Testoni F., Angelelli B., Pannuti F. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. Cancer Chemother Pharmacol. 21:1988;221-228.
16. Dobbs NA, Twelves CJ, Rizzi P, Warwick JD, Metivier EM, Williams R, Johnson PJ Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity. Cancer Chemother Pharmacol. 34(5):1994;405-440.
17. Miller AB., Hoogstraten B., Staquet H. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
18. Shepherd F.A., Feld R., Blackstein M. et al. Administration of high dose bolus epirubicin (EPI) is not associated with increased cardiotoxicity. Proc Am Soc Clin Oncol. 8:1989;335.
19. Klastersky J., Sculier J.P., Ravez P. et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol. 4:1986;1780-1786.
20. Shinkai T., Saijo N., Eguchi K. et al. Cisplatin and Vindesine combination chemotherapy for non-small lung cancer: a randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res. 77:1986;782-789.
21. Berthaud P, Le Chevalier T, Ruffié P. Phase I-II study of navelbine (vinorelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 1992;28:1863-1865.
22. Bretti S., Berruti A., Gorzagno G. et al. Multicenter phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients. Lung Cancer. 14:1996;353-360.
23. Depierre A., Chastang Cl., Qoix E. et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol. 5:1994;37-42.